OncoTherapy Science, Inc.
Notice Regarding Large-Scale Exercise of the 38th Stock Acquisition Rights (with Exercise Price Adjustment Clause) through Third-Party Allotment
Reporting a large exercise of 38th stock acquisition rights. From June 1 to 9, 9,600,000 shares were issued, with 96,000 exercised (12.06% of total issued), and unexercised rights reduced to 150,000. Unexercised rights at the end of the previous month were 246,000 rights, with total issued shares of 39,864,3700. Future exercise status is unknown.
Key Figures
- Issued shares: 9,600,000 shares
- Number of stock options exercised: 96,000 units
- Unexercised stock options (current): 150,000 units (15,000,000 shares)
AI要約
Background and Key Points
This notice concerns a large exercise of the 38th stock acquisition rights (with an exercise price adjustment clause) issued through a third-party allocation. The relevant period is June 1–9, 2026, with 9,600,000 shares issued; of these, 96,000 rights were exercised (12.06% of total issued). As of now, unexercised rights are 150,000 (15,000,000 shares), down from 246,000 rights (24,600,000 shares) at the end of the prior month.
Impact on Shareholders and Outlook
The large exercise may affect the number of issued shares and potentially dilute shareholders. The trajectory of unexercised rights will depend on future market conditions and the application of the exercise price adjustment clause. Additional disclosures refer to the related notice published on November 21, 2025, and ongoing updates should be monitored.
OncoTherapy Science, Inc.
Company overview · Stock price · Financial data · All IR
